Cerity Partners’s Maravai LifeSciences MRVI Stock Holding History

Cerity Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.33M	Buy	469,341 +1,426	+0.3%	+$4.83K	﹤0.01%	1702
2025 Q4	$1.52M	Buy	+467,915	New	+$1.58M	﹤0.01%	1496
2024 Q4	–	Sell	-11,702	Closed	-$97.2K	–	2532
2024 Q3	$97.2K	Buy	+11,702	New	+$101K	﹤0.01%	2427
2024 Q2	–	Sell	-13,938	Closed	-$121K	–	2338
2024 Q1	$121K	Buy	+13,938	New	+$94.3K	﹤0.01%	2180
2022 Q4	–	Sell	-21,239	Closed	-$542K	–	1512
2022 Q3	$542K	Sell	21,239 -4,898	-19%	-$123K	0.01%	690
2022 Q2	$743K	Buy	26,137 +2,055	+9%	+$65.1K	0.01%	624
2022 Q1	$850K	Buy	+24,082	New	+$807K	0.01%	474
2021 Q2	–	Sell	-15,000	Closed	-$535K	–	728
2021 Q1	$535K	Sell	15,000 -57	-0.4%	-$1.89K	0.01%	437
2020 Q4	$422K	Buy	+15,057	New	+$419K	0.01%	441

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cerity Partners's MRVI Position: Q1 2026 in Review

Cerity Partners increased its Maravai LifeSciences (MRVI) stake by 0.3% in Q1 2026, buying an estimated $4.83K and bringing the position to 469,341 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1702.

Cerity Partners first reported a position in MRVI in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.52M in Q4 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Cerity Partners held 469,341 shares of Maravai LifeSciences worth $1.33M as of Q1 2026.
Cerity Partners bought 1,426 Maravai LifeSciences shares in Q1 2026, an estimated $4.83K.
Maravai LifeSciences made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #1702 holding.
Cerity Partners first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 9 quarters since.
Cerity Partners's Maravai LifeSciences position peaked at $1.52M in Q4 2025.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.